Meeting
2015 Gastrointestinal Cancers Symposium
Evaluation of the CpG island methylator phenotype as a predictive biomarker for adjuvant oxaliplatin-based chemotherapy in colorectal cancer.
Authors
Stacey Shiovitz
Fred Hutchinson Cancer Research Center, Seattle, WA
Stacey Shiovitz , Chen Wu , Ming Yu , Georgia Gourgioti , Georgia Raptou , Vassiliki Kotoula , George E. Pentheroudakis , Konstantine T. Kalogeras , George Fountzilas , William M. Grady
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 592)
DOI
10.1200/jco.2015.33.3_suppl.592
Abstract #
592
Poster Bd #
B36
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.
First Author: Hyun-Jung Lee
Poster
2011 ASCO Annual Meeting
CpG island methylator phenotype and KRAS mutation status as prognostic markers in patients with resected colorectal cancer.
First Author: D. H. Koo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2012 Gastrointestinal Cancers Symposium
A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803.
First Author: Chloe Evelyn Atreya